Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY23 results · Apr–Jun 2022
Ajanta Pharma reported revenue from operations of ₹950.93 crore (up 27.1% from Q1 FY22) and net profit of ₹174.62 crore (up 0.5% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 950.93 | 747.99 | +27.1% | 870.29 | +9.3% |
| Other income | 32.76 | 32.63 | +0.4% | 29.48 | +11.1% |
| Total income | 983.69 | 780.62 | +26.0% | 899.77 | +9.3% |
| Profit before tax | 221.86 | 220.45 | +0.6% | 197.67 | +12.2% |
| Net profit for the period | 174.62 | 173.75 | +0.5% | 151.21 | +15.5% |
| EPS, basic (₹) | 13.63 | 20.08 | not comparable | 17.70 | not comparable |
| Net margin (%) | 18.4 | 23.2 | 17.4 |
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 850.29 | 742.72 | +14.5% | 765.63 | +11.1% |
| Other income | 35.42 | 31.00 | +14.3% | 28.42 | +24.6% |
| Total income | 885.71 | 773.72 | +14.5% | 794.05 | +11.5% |
| Profit before tax | 190.35 | 233.09 | −18.3% | 178.30 | +6.8% |
| Net profit for the period | 150.37 | 193.46 | −22.3% | 134.84 | +11.5% |
| EPS, basic (₹) | 11.74 | 22.36 | not comparable | 15.79 | not comparable |
| Net margin (%) | 17.7 | 26.0 | 17.6 |
Consolidated
- Filed with BSE
- 29 Jul 2022, 12:47 IST
- Board meeting
- 28 Jul 2023
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jul 2022, 12:47 IST
- Board meeting
- 28 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE